Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits

Hyperglycemia is an undisputed epidemiological risk factor for microvascular complications in both type 1 and type 2 diabetes, integral in their causal pathways. Importantly, interventions that reduce the hyperglycemic burden in patients with either type of diabetes reduce the risk of microvascular...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Pharm Policy Pract
Hauptverfasser: McGuire, Darren K., Inzucchi, Silvio E., Johansen, Odd Erik, Rosenstock, Julio, George, Jyothis T., Marx, Nikolaus
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2021
Schlagworte:
Commentary
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048355/
https://ncbi.nlm.nih.gov/pubmed/33858511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40545-020-00295-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge